UK Genomics Medicine Start-up Congenica Ltd Wins Genomics England Competition
News May 06, 2014
Cambridge based Congenica Ltd has announced that it has been one of several Small Business Research Initiative competition awards funded by the UK Department of Health and managed by Genomics England.
This funding will be used by Congenica to further develop it’s SAPIENTIA™ platform that provides a novel, modular, and scalable data analytics pipeline for the annotation and clinical interpretation of genomic sequence data in both human genetic disease testing and research environments.
Tom Weaver, Congenica’s CEO, said: “Winning this competition is very important for a small start-up company like ours as it demonstrates our potential and a measure of how critical the analysis tools we are developing will be for supporting national scale screening projects, including Genomics England’s fantastic ambition to sequence 100,000 genomes in a clinical context.”
Data analytics that allow the intelligent interpretation of genome sequence and clinical phenotypes in a safe, affordable and scalable manner is the next challenge as genomic technology transforms the way doctors diagnose disease and decide on the best treatment choices.
Congenica’s first product is built upon world leading technology developed by the Wellcome Trust Sanger Institute that has delivered many thousands of genomes and it is the company’s vision to apply this technology in the clinic in order to make a real difference in the treatment and outcome of patients with genetic disease.
Animal venoms are the subject of study at research center based at the Butantan Institute in São Paulo. But in this case, the idea is not to find antidotes, but rather to use the properties of the venoms themselves to identify molecular targets of diseases and, armed with that knowledge, develop new compounds that can be used as medicines.